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The rare and heterogeneous kidney disorder C3 glomerulopathy (C3G) is characterized by
dysregulation of the alternative pathway (AP) of the complement system. C3G is often
associated with autoantibodies stabilizing the AP C3 convertase named C3 nephritic
factors (C3NeF). The role of classical pathway (CP) convertase stabilization in C3G and
related diseases such as immune complex-mediated membranoproliferative
glomerulonephritis (IC-MPGN) remains largely unknown. Here, we investigated the CP
convertase activity in patients with C3G and IC-MPGN. Using a refined two-step
hemolytic assay, we measured the stability of CP convertases directly in the serum of
52 patients and 17 healthy controls. In four patients, CP convertase activity was
prolonged compared to healthy controls, i.e. the enzymatic complex was stabilized. In
three patients (2 C3G, 1 IC-MPGN) the convertase stabilization was caused by
immunoglobulins, indicating the presence of autoantibodies named C4 nephritic factors
(C4NeFs). Importantly, the assay also enabled detection of non-immunoglobulin-
mediated stabilization of the CP convertase in one patient with C3G. Prolonged CP
convertase activity coincided with C3NeF activity in all patients and for up to 70 months of
observation. Crucially, experiments with C3-depleted serum showed that C4NeFs
stabilized the CP C3 convertase (C4bC2a), that does not contain C3NeF epitopes. All
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Margarita López-Trascasa,






This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 27 May 2021
Accepted: 20 July 2021
Published: 11 August 2021
Citation:
Michels MAHM, van de Kar NCAJ,
van Kraaij SAW, Sarlea SA, Gracchi V,
Engels FAPT, Dorresteijn EM,
van der Deure J, Duineveld C,
Wetzels JFM, van den Heuvel LPWJ,
and Volokhina EB (2021) Different
Aspects of Classical Pathway








published: 11 August 2021
doi: 10.3389/fimmu.2021.715704
patients with prolonged CP convertase activity showed clear signs of complement
activation, i.e. lowered C3 and C5 levels and elevated levels of C3d, C3bc, C3bBbP,
and C5b-9. In conclusion, this work provides new insights into the diverse aspects
and (non-)immunoglobulin nature of factors causing CP convertase overactivity in
C3G/IC-MPGN.
Keywords: C3 glomerulopathy, classical complement pathway, autoantibody, C3 convertase, C4 nephritic factors
(C4NeFs), C3 nephritic factors (C3NeFs)
INTRODUCTION
C3 glomerulopathy (C3G) is an umbrella term for kidney diseases
characterized by glomerular inflammation and accumulation of
breakdown fragments of complement component C3 in the
glomeruli (1, 2). The diagnosis requires a kidney biopsy showing
C3 staining that is dominant over other immune reactants by
immunofluorescence microscopy. The two major subgroups
within the classification of C3G are dense deposit disease (DDD)
and C3 glomerulonephritis (C3GN). DDD is distinguished from
C3GN by characteristic, highly electron-dense, intramembranous
sausage-shaped deposits in electronmicroscopy (1, 2). C3G patients
can present with various symptoms, such as proteinuria, hematuria,
hypertension, and decreased kidney function. Current therapy
encompasses antihypertensive agents and immunosuppressive
drugs such as prednisone and mycophenolate mofetil. Despite
this treatment, many patients progress to kidney failure within
ten years (2, 3).
Before the definition of C3G was introduced in 2010 (4) and
consensus on the definition was further implemented by a group
of specialists in 2012-2013 (1), the membranoproliferative
glomerulonephritis (MPGN) classification was used by
physicians. This is a rather non-specific pathology term that
besides C3G includes immune complex-mediated MPGN (IC-
MPGN), which is characterized by significant staining for
immunoglobulins (Igs). The new umbrella classification of
C3G was developed to emphasize the underlying disease
process: the dysregulation of the alternative pathway (AP) of
the complement system. This was meant to encourage the
pathologist and nephrologist to start investigations of
complement abnormalities, also in view of complement-
targeting drugs that are being developed (1, 4). Indeed, in 40-
90% of all C3G cases Igs binding the central AP enzyme, the AP
C3 convertase [C3bBb(P)], are found in the blood (5–8). These
autoantibodies are named C3 nephritic factors (C3NeFs) and
stabilize the convertase complex, prolonging its C3-cleaving
activity. In addition, aberrations in genes encoding AP
components and/or regulators can be found in approximately
20% of C3G patients (5, 8). Nonetheless, a recent whole-genome
sequencing study found that not rare complement gene
variations, but HLA type was associated with C3G, implicating
that an autoimmune mechanism underlies the disease in most
cases (9). Interestingly, abovementioned AP dysregulations such
as C3NeFs are also found in a substantial number of IC-MPGN
patients (5, 10, 11). In some cases, distinguishing between C3G
and IC-MPGN based on immunofluorescence microscopy
remains difficult, and some patients with IC-MPGN may
evolve to C3G and vice versa (2). In a small number of
patients still no pathogenic acquired or genetic factors can
be identified.
The AP serves as a surveillance mechanism for complement
activity due to its constant low rate of activation. In addition, the
pathway encompasses a powerful loop to rapidly amplify the
activity of all complement pathways, including the classical
pathway (CP) and lectin pathway that are activated by specific
pattern recognition (12–14). Although AP dysregulation has
been extensively studied in the context of C3G, less research
has focused on the involvement of CP convertase dysregulation.
Recently, C4 nephritic factors (C4NeFs) have been reported in
three C3G patient cohorts with a prevalence of 3-15% (15–17). In
analogy with C3NeFs, C4NeFs are autoantibodies that bind and
stabilize the CP C3/C5 convertases [C4bC2a(C3b)] resulting in a
prolongation of the half-life of these enzyme complexes from
minutes to hours. C4NeFs have also been previously reported in
patients with (IC-)MPGN (16, 18–20), post-infectious
glomerulonephritis (21), systemic lupus erythematosus (18, 22,
23), Sjögren syndrome (18), and in one patient with sepsis caused
by a Neisseria meningitidis infection (24). Nonetheless, studies
on the presence and relevance of C4NeFs in complement-
mediated kidney diseases such as C3G and IC-MPGN are still
limited and often not part of the standard laboratory workup.
Furthermore, there is no standardization of the different assays
that are being used.
In this work, we investigated whether CP convertase
overactivity occurred in our patient cohort consisting of 45
patients with C3G and 7 patients with IC-MPGN. First, we
validated a two-step CP convertase activity assay measuring the
stability of CP convertases directly in the serum of patients, to
screen for factors prolonging the CP convertase activity. Next, we
characterized the nature of these factors and investigated their
prevalence in the disease course and relation to complement
activation markers.
MATERIALS AND METHODS
Sample Collection and Inclusion
Between July 2001 and March 2020, blood samples from 116
patients whose physicians indicated a suspicion of C3G or
MPGN were sent to the Radboud university medical center for
complement investigation corresponding to their suspected
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disease. All samples were measured for abnormal CP convertase
activity. For 58 patients the final diagnosis could be retrieved
(Figure 1). Fifty-two patients met the inclusion criteria of a final
diagnosis of C3G (1) or idiopathic IC-MPGN: 45 patients had
C3G (24 DDD, 17 C3GN, and 4 cases that could not be further
classified due to lack of electron microscopy data) and 7 had IC-
MPGN. Of note, P1 and P2 have been described before as P25
(25) and P3 (26) and P10 (26), respectively. Six patients had
another glomerular diagnosis: 2 monoclonal gammopathy of
renal significance, 2 atypical hemolytic uremic syndrome, 1
hemolytic uremic syndrome, and 1 systemic lupus
erythematosus. These six patients and the patients with
unknown definite diagnosis were excluded. Furthermore,
samples collected from 17 healthy adult controls were included
in this study.
The study was performed in accordance with the appropriate
version of the Declaration of Helsinki. Whole blood samples
were processed within 1 hour after sampling according to the
standard protocol (25). To obtain normal human serum (NHS)
and normal human plasma (NHP), 17 control sera and 17
control ethylenediaminetetraacetic acid (EDTA)-plasma
samples were pooled, respectively.
Sensitized Sheep Erythrocytes
Sheep erythrocytes (ShE) suspended in Alsever’s solution were
obtained from Håtunalab AB (Bro, Sweden). For each
experiment, freshly sensitized ShE working suspensions were
prepared as described previously (27), by washing the
erythrocytes in dextrose gelatin veronal buffer (DGVB++; 45
mM veronal buffer, pH 7.4, 72 mM NaCl, 139 mM D-glucose,
0.1% gelatin, 1 mM MgCl2, 0.15 mM CaCl2) and incubating
them with 1000x diluted amboceptor (Siemens Healthcare,
Erlangen, Germany) for 20 min at 37°C. In each experiment,
erythrocyte working suspensions were calibrated to yield an
absorbance of 1.8-2.2 at 405 nm when 10x diluted in water.
Immunoglobulin Purification
The Ig fractions were isolated from 0.2-1.0 mL EDTA-plasma
(P1, P4, and NHP) or serum (P2, P3, and NHS) samples as
previously described (25), using Nab™ protein A/G spin
columns (Thermo Fisher Scientific, Waltham, MA, USA). After
purification and dialysis, Ig fractions were concentrated in
phosphate buffered saline to the initial sample volume. Final
protein concentrations were measured using NanoDrop
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA)
FIGURE 1 | Flow chart of sample inclusion. All patient samples were measured for prolonged classical pathway activity, i.e. C4 nephritic factor (C4NeF) activity, but
only the 52 patients with a final diagnosis of C3 glomerulopathy (C3G) or immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) were
included in this study. C3 nephritic factor (C3NeF) activity, i.e. prolonged alternative pathway activity, was measured in the number of patients indicated between
brackets. DDD, dense deposit disease; C3GN, C3 glomerulonephritis; MGRS, monoclonal gammopathy of renal significance; HUS, hemolytic uremic syndrome;
aHUS, atypical HUS; SLE, systemic lupus erythematosus.
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and varied between 2.4 and 9.8 mg/mL for the patient samples
and between 10.1 and 11.1 mg/mL for the control pools.
Classical Pathway Convertase
Activity Assay
Activity of CP C3/C5 convertases was measured using a two-step
convertase activity assay that follows the same principles as
described previously (15, 28, 29) (Supplementary Figure 1). In
the first step, test serum was incubated for different time periods
with sensitized ShE in presence of a C5-inhibitor to allow CP
activation and CP convertase assembly up to the level of C5
convertases. After a washing step, preformed convertase
complexes were allowed to generate C5b-9 and subsequent
hemolysis using guinea pig serum in presence of EDTA.
Per experimental time point, 10 µL of sensitized ShE were
mixed with 20 µL DGVB++ containing 10 nM of the C5-inhibitor
eculizumab (Alexion Pharmaceuticals, Cheshire, CT, USA).
Subsequently, 20 µL of 1.9-2.5% test serum or EDTA-plasma
diluted in DGVB++ (for a final sample concentration in the well of
0.75-1%) was added at different time points to allow convertase
assembly for 20, 10, 5, 2.5, 1.0, and 0.5 min. Where applicable,
NHS or C3-depleted serum (A314, Complement Technology,
Tyler, TX, USA) were first mixed with purified Igs in a volume
ratio of 1:1, 1:3, or 1:5 before being added as the test sample. Then,
150 µL of ice-cold 40 mM EDTA–gelatin veronal buffer (EDTA–
GVB, 4.41 mM veronal buffer, 0.1% gelatin, 130 mM NaCl, pH
7.4) was added, after which the cells were washed and collected by
centrifugation (2 min, 1,000 g, room temperature). For the second
step, erythrocytes were incubated for 60 min with 50 µl of 2.5%
guinea pig serum (Envigo, Venray, the Netherlands) in EDTA-
GVB as a source of C5b-9 components, supplemented with 50 µl
of DGVB++ buffer. All incubation steps above were performed in
V-shaped 96-well plates (Greiner Bio-One) at 37°C with 600 rpm
agitation in a VWR® Incubating Microplate Shaker with 3 mm
orbit (VWR International). Finally, the supernatant was collected
by centrifugation and transferred to flat-bottom 96-well plates
(Greiner Bio-One). Hemolysis was quantified as percentage of full
lysis generated by an equal amount of erythrocytes in water: (A405
test sample − A405 blank)/(A405 full lysis − A405 blank) × 100%.
Other Complement Investigations
C3NeF activity was measured using a two-step hemolytic AP
convertase activity assay (25). Levels of C3bBbP, C3bc, C5b-9,
C5, properdin, Factor H, and Factor I were measured in the
appropriate EDTA-plasma or serum samples with enzyme-
linked immunosorbent assays (ELISA). Protocols were
described before (26, 27, 30, 31), but for the measurement of
properdin in EDTA-plasma samples a monoclonal mouse anti-
human properdin antibody (A233, Quidel, San Diego, CA, USA)
and goat anti-human properdin antibody (Nordic-MUbio,
Susteren, the Netherlands) were used. For all ELISAs patient
material that gave a value outside the reference range was used as
a positive control. The C3, C4, and C3d levels, and the results of
the genetic analysis were obtained from the patient files. Coding
regions of the complement genes CFH, CFHR5, CFI, CD46, C3,
and CFB were screened for rare genetic variants (i.e. <1% allele
frequency) according to previously described protocol (32).
In addition, multiplex ligation-dependent probe amplification,
using the SALSA® P236 probe mix and reagent kits of MRC
Holland (Amsterdam, the Netherlands), was performed to
analyze the CFH/CFHR region in all patients.
Statistical Analysis
Where indicated, data were analyzed using two-way analysis of
variance with Bonferroni’s post-test using GraphPad Prism 5.03
for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
CP Convertase Activity in Healthy Controls
To establish the normal CP convertase activity profile, 17 healthy
control sera were analyzed. These individual controls showed
activity profiles that were comparable to each other and to NHS
(Figure 2). Maximal CP convertase activity was reached after
0.5-2.5 min, followed by a sharp decrease in hemolysis in all
samples at 5 min of incubation and onwards.
We used these data to define cut-off criteria for detecting
aberrant, prolonged convertase activity in patient samples.
Analogous to the AP convertase activity assay published
previously (25), we determined the ratio between the highest
achieved hemolysis and the hemolysis at 10 min of incubation
(top/t10 ratio) to describe the CP convertase decay. Healthy
controls showed a top/t10 ratio of 7.7 ± 3.1 (mean ± SD).
Prolonged activity, i.e. delayed decay, was defined as a top/t10
ratio below the mean - 2SD of healthy controls, which is below
1.6. Hemolytic activity overall was also taken into account: the
area under the curve of a sample should be comparable to or
higher than that of NHS to be considered as aberrant.
FIGURE 2 | Classical pathway convertase activity in healthy controls.
Classical pathway convertase activity was measured by incubating sensitized
sheep erythrocytes with sera obtained from 17 healthy individuals. Normal
human serum (NHS) and heat-inactivated NHS (hi-NHS) were used as assay
controls. Hemolysis levels are presented as percentage of full lysis of
erythrocytes in water. Results represent means of at least three independent
measurements for each sample. Standard deviations have been omitted for
better visibility.
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CP Convertase Activity Is Prolonged
in Four Patients
We then screened for deviant CP convertase activity in the
samples of 52 C3G/IC-MPGN patients whose samples were
collected for complement investigation in the context of their
disease. The patients had a median (IQR) age at the time of
investigation of 15 (8–18) years and 63% was female. The
samples of four patients showed prolonged CP convertase
activity (Figure 3). These activity profiles were characterized
by top/t10 ratios below 1.6 and an area under the curve higher
than that of NHS (Table 1). Three of the four patients with
prolonged CP convertase activity had a biopsy-proven diagnosis
of C3G (P1, P2, and P3), and one patient had biopsy-proven IC-
MPGN (P4). In two patients, rare genetic variants were found in
C3 (P2) and CFHR5 (P4) complement genes (Table 1). Of note,
no prolonged CP convertase activity was observed in the six
excluded patients diagnosed with other glomerular
disorders (Figure 1).
CP Convertases Are Stabilized by
Immunoglobulins (C4NeFs) in Only
Three of the Four Patients
To investigate whether Igs, i.e. C4NeFs, were responsible for the
increased convertase stability in the sera of patients P1-P4, we
purified the Igs from the samples. Purified Ig fractions were
concentrated in phosphate buffered saline to the initial sample
volume and added to NHS in different volume ratios in the
convertase activity assay (Figure 4). The Igs of P1, P2, and P4
dose-dependently prolonged the CP convertase activity,
indicating C4NeF presence (Figures 4A–C). In contrast, the
Igs of P3 did not support CP convertase stabilization, even when
added in a five-fold excess to NHS (Figure 4D).
C4NeF Immunoglobulins Stabilize
the C4bC2a Convertase
In the first step of the CP convertase activity assay both C3
convertases (C4bC2a) and C5 convertases (C4bC2aC3b) are
assembled and further complement activation is blocked by
eculizumab. C3b is also a component of AP C3 (C3bBbP) and C5
(C3bBbPC3b) convertases. Thus, to specifically analyze the CP C3
convertase-stabilizing activity of C4NeFs, C3-depleted serum was
used in thefirst step of the assay so that onlyC4b2a could be formed.
Addition of the Ig fractions from the patients showing Ig-mediated
convertase stabilization in NHS, i.e. P1, P2, and P4, to C3-depleted
serumresulted inprolongedCPC3convertase activity profiles in all
cases (Figures 5A–C). The hemolysis levels at t10 and t20 were
significantly elevated compared to C3-depleted serum to which
control Igs were added (P<0.001).
C4NeF and C3NeF Activity During
Patient Follow-Up
In the C3G/IC-MPGN cohort, 63% (29/44 C3G, 3/7 IC-MPGN) of
the patients displayed prolonged AP convertase activity, i.e. C3NeF
activity (Figure 1). All four patients that showed prolonged CP
convertase activity, from now on defined as C4NeF activity
regardless of the (non-)Ig nature, also displayed C3NeF activity.
The C3NeF activity was Ig-mediated in all these patients.
Autoantibodies to FactorHwere not detected in any of the patients.
We then monitored the activity of the AP and CP convertase-
stabilizing factors during patient follow-up. Both the C4NeF and
FIGURE 3 | Prolonged classical pathway convertase activity profiles in four
patients. Classical pathway convertase activity was measured by incubating
sensitized sheep erythrocytes with normal human serum (NHS) or with patient
samples. Depicted are the activity profiles for patients P1, P2, P3, and P4,
that tested positive for prolonged convertase activity as their top/t10 ratios
were <1.6 in at least three measurements performed. Representative runs of
these samples are shown. Data for NHS are given as the mean and range
from the four experiments in which the positive patients were detected. The
area under the NHS curve is indicated in grey. Hemolysis levels are presented
as percentage of full lysis of erythrocytes in water.
TABLE 1 | Details of the patients showing prolonged classical pathway convertase activity.








Genetic aberrations (heterozygous) Minor allele frequencyc
P1 M 15 DDD 1.0 (1.0 – 1.1) 435% –
P2 F 16 C3GN 1.1 (1.0 – 1.2) 313% C3 c.691A>C (p.Ser231Arg) Not available
P3 F 10 C3GN 1.4 (1.4 – 1.5) 218% –
P4 M 16 IC- MPGN 1.1 (1.1 – 1.3) 168% CFHR5 c.485_486dup (p.Glu163Lysfs*10)d 0.68%
aAge at time of sample collection for investigation.
bObtained from three independent experiments.
cAccording to the gnomAD database.
dThis patient additionally carries the CFH Tyr402His variant.
AUC, area under the curve; NHS, normal human serum; DDD, dense deposit disease; C3GN, C3 glomerulonephritis; IC-MPGN, immune complex-mediated membranoproliferative
glomerulonephritis.
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C3NeF activity of P1 (Figure 6), P2 (Figure 7A), P3 (Figure 7B),
and P4 (Figure 7C) persisted over the disease course, up to 70
months of follow-up. Patients received standard therapy, including
corticosteroids, mycophenolate mofetil, angiotensin converting
enzyme (ACE) inhibitors, and diuretics, but no B cell-directed
therapy or complement blockers such as eculizumab.
Complement Activation Profiles During
Patient Follow-Up
We also looked in detail at the complement profiles of the patients
during follow-up by measuring the levels of the complement
components, complement activation markers, and complement
regulators. All four patients showed evident and consistent signs of
complement activation, as indicated in the serum or plasma by very
lowC3 levels, elevated levels of theC3 breakdownproducts C3d and/
or C3bc, elevated levels of C3bBbP (properdin-stabilized AP C3
convertase) and C5b-9, and decreased levels of C5 (Figure 8). In
contrast to the persistent consumption of C3 in all patients analyzed,
C4 levelswereonlydecreased atpresentation inP2andP3.Properdin
levels were decreased in P3 and P4 and in some samples of P2. The
negative complement regulatory proteins FactorH and Factor I were




FIGURE 4 | Classical pathway convertase activity profiles of control serum supplemented with patient immunoglobulin fractions. Sensitized sheep erythrocytes were
incubated with normal human serum (NHS) mixed with an equal (1:1) or excess volume (1:3 and 1:5) of immunoglobulins (Igs) purified from the EDTA-plasma of
patient P1 (A) and P4 (C) or from the serum of P2 (B) and P3 (D). As a negative control, Igs purified from normal human plasma (NHP) or NHS, depending on the
source of the patient Igs, were added in similar ratios. The patient sera were used as positive controls. Hemolysis levels are presented as percentage of full lysis of
erythrocytes in water. Concentration series were tested once. hi-NHS, heat-inactivated NHS.
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Compared to patients without C4NeF activity, the
complement markers C3bBbP, C3bc, C5b-9, C5, and
properdin tended to be more strongly increased or decreased
in the four patients with C4NeF activity, especially when
compared to patients without C3NeF activity (Supplementary
Figure 2). When comparing the patients with both C4NeF and
C3NeF activity with patients with C3NeF activity alone, the low
C5 and properdin levels were most noticeable.
Clinical Features During Follow-Up
Patient 1
This male patient presented at the age of 7 years with
macroscopic hematuria and nephrotic range proteinuria with
normal renal function. C3 serum levels were low (60 mg/L) but
with normal serum C4 (260 mg/L). Serology findings for
antineutrophil cytoplasmic antibody (ANCA), antinuclear
antibody (ANA), and antistreptolysin O (ASO) titer were all
negative. The kidney biopsy findings were consistent with DDD.
With treatment including intravenous methylprednisolone
therapy for 3 days followed by oral steroids, ACE inhibitor,
and hydrochlorothiazide he reached partial remission, i.e.
normal renal function with still some mild persisting
proteinuria. His follow-up described in this study, however,
started at the age of 15 years, when he presented again with
nephrotic range proteinuria. This was preceded by diarrhea
followed by general fatigue 5 weeks before presentation. C3
serum levels were again low (82 mg/L), C3d levels elevated
(32.2 mg/L), and serum C4 levels normal (213 mg/L). This
time exanthemata-like, non-itchy skin lesions were present at
his face, trunk, arms, and legs as well as a staggering painful knee
and ankles without redness and swollenness. Skin biopsy showed
neutrophilic dermatosis. Fever developed during intravenous
methylprednisolone treatment. Blood culture demonstrated a
N. meningitidis C infection for which he was treated with
antibiotics. No drusen were found with ophthalmologic
examination. Intravenous methylprednisolone was given and
followed by oral steroids, mycophenolate mofetil, and ACE
inhibition. The urinary protein/creatinine ratio declined from
2000 mg/mmol in the acute phase to 486 mg/mmol after
5 months and 65 mg/mmol after 1 year. His serum albumin
rose from 15 g/L in the acute phase towards 38 g/L 8 months
after starting his treatment for the relapse. His renal function
remained normal during this period with serum creatinine levels
between 36-45 µmol/L. Low complement C3 levels as well as
increased C3d levels persisted despite improvement in
proteinuria. At the age of 18 years the patient was transferred
to the adult nephrology clinic with normal serum creatinine
(40 µmol/L), a urinary protein/creatinine ratio that varied
between 69-132 mg/mmol, and normal blood pressure while
receiving mycophenolate mofetil and ACE inhibition.
Patient 2
This girl was diagnosed at the age of 16 years with nephrotic
syndrome with normal estimated glomerular filtration rate
(eGFR) and was treated with a high dose of steroids and
mycophenolate mofetil. Kidney biopsy taken on admission
showed a mesangial proliferative glomerulonephritis with some
global glomerulosclerosis and subepithelial humps. No staining
for IgA, IgG, IgM, kappa or lambda light chains on
immunofluorescence, marginal staining in capillaries for C1q
and C3, but strong staining for C4d along the glomerular
basement membrane were observed. Diffuse intramembranous,
electron dense deposits were present on electron microscopy. On
admission low serum C3 (40 mg/L), low C4 (50 mg/L), high C3d




FIGURE 5 | Classical pathway C3 convertase (C4b2a) stabilization by patient
immunoglobulins. Sensitized sheep erythrocytes were incubated with C3-
depleted serum supplemented with immunoglobulins (Igs) from P1 (A), P2
(B), or P4 (C) in a 1:3 volume ratio. Igs from normal human plasma (NHP)
were used as a control. Hemolysis levels are presented as percentage of full
lysis of erythrocytes in water. Data are presented as the mean and the
standard deviation of three independent experiments. Significance values
according to two-way analysis of variance with Bonferroni post-test with C3-
depleted serum + NHP Igs as the control condition are given for t5, t10, and
t20: ***P < 0.001; **P < 0.01; ns, not significant. NHS, normal human serum;
hi-NHS, heat-inactivated NHS.
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observed, and these values did not change during her three year
follow-up, except for C4 normalization within one year.
Although in follow-up she did not have peripheral and
general edema, her serum albumin remained low (21-27 g/L)
and her urinary protein/creatinine ratio ranged between 160-
450 mg/mmol. Another renal biopsy performed at the age of 18
years demonstrated the pattern of C3GN with still extensive
mesangial proliferation with mild endocapillary hypercellularity
as well as endothelial, epithelial, intramembranous, endothelial,
and mesangial depositions. Immunofluorescence showed this
time C3 3+ next to C1q 1+, IgG, and IgM 1+. Unfortunately,
no staining for C4d was performed. No glomerulosclerosis or
interstitial fibrosis or tubular atrophy were seen. While on low
dose of steroids, mycophenolate mofetil, losartan, and
hydrochlorothiazide, she was transferred at 18 years to the
adult nephrology clinic having a serum creatinine of 80 µmol/L
and be ing normotens ive but s t i l l w i th nephrot ic
range proteinuria.
Patient 3
This female patient presented at the age of 10 years at the
pediatric nephrology clinic. She had periorbital edema for
already 2-3 weeks. At presentation she had a normal renal
function with an eGFR of 136 ml/min/1.73 m2 (serum
creatinine 41 µmol/L) with nephrotic range proteinuria
(urinary protein/creatinine ratio 1656 mg/mmol) and
microscopic hematuria. She started with oral steroids for the
presumed minimal change nephrotic syndrome. After 4 weeks of
treatment she had responded partially with decline in proteinuria
(urinary protein/creatinine ratio 717 mg/mmol) and no
peripheral edema. Serum complement C3 level and C4 were
very low (90 mg/L) and low (70 mg/L), respectively, and serum
FIGURE 6 | C4 nephritic factor and C3 nephritic factor activity of patient P1 during follow-up. Samples from P1 collected over the disease course were tested for
prolonged classical pathway activity, i.e. C4 nephritic factor (C4NeF) activity, and for prolonged alternative pathway activity, i.e. C3 nephritic factor (C3NeF) activity.
Collection dates are presented as time after acute presentation in months (+mo). Hemolysis levels are presented as percentage of full lysis of erythrocytes in water.
Results are shown as mean and range of two independent experiments. For the C4NeF activity assay, the positive control (PC) is the sample of P1 collected 32 mo
after presentation. Part Rem, partial remission; NHS, normal human serum; hi-NHS, heat-inactivated NHS.
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C3d level was elevated (16.9 mg/L). Serology findings for ANCA,
ANA, andASO titer were all negative. Kidney biopsy demonstrated
a mesangioproliferative glomerulonephritis with no chronic
lesions. C3 was prominently present on immunofluorescence
microscopy (3+), and electron microscopy showed no
intramembranous dense deposits. The referring center diagnosed
the patient as C3GN. Mycophenolate mofetil was added to the
steroids therapy followed byACE inhibition, and later losartan was
added. Six months later she is feeling well with no edema and a
normal renal function, normotensive but still nephrotic range
proteinuria (urinary protein/creatinine ratio 200-400 mg/mmol).
The serumC3 level (150mg/L) andC4 level 130mg/L) are still low,
and C3d remained elevated (22 mg/L). Her treatment consists of
daily low steroids, mycophenolate mofetil, ramipril, and losartan.
Patient 4
This boy presented at the age of 15 years with nephrotic range
proteinuria, microscopic hematuria, and general edema at the
emergency department. Blood pressure was 126/86 mmHg. One
week before admission he had a possible throat infection for
which he visited the general practitioner. His medical history
mentioned an autism spectrum disorder and mental retardation.
His laboratory results showed a low serum albumin (14 g/L) and
low-normal eGFR 81 ml/min/1.73 m2. The urinary protein/
creatinine ratio on admission was 760 mg/mmol. Serology
findings for ANCA, ANA, and ASO titer were all negative.
Serum C3 was low (68 g/L), C3d elevated (28.6 mg/L), and C4
normal (178 mg/L). Due to the extreme fluid overload (estimated
18 L), fluid and salt restriction as well as diuretics were
immediately started. Differential diagnosis mentioned post-
infectious glomerulonephritis, IgA nephropathy, lupus
nephritis, and C3G. Several attempts to perform a kidney
biopsy under anesthesia in the acute phase of the disease failed
due to his persistent refusals. In the light of the negative results for
autoimmune diseases (see above) in combination with very low
serological C3 level, elevated complement activation markers, and
the presence of C3NeF, C3G was suggested. Treatment including
high dose of steroids, mycophenolate mofetil, ACE inhibition, and
diureticswas started. Fortunately, threeweeks after the start of therapy
a renal biopsy could be performed and showed an IC-MPGN
without extracapillary proliferations and no interstitial-tubular
damage. Immunofluorescence demonstrated granular deposits
in the capillary wall: C3 3+, IgG 2+, IgM 1/2+, lambda 2+, kappa
1/2+, with no IgA or C1q. No chronic lesions were observed.
A B
C
FIGURE 7 | C4 nephritic factor and C3 nephritic factor activity of patients P2, P3, and P4 during follow-up. Samples from P2 (A), P3 (B), and P4 (C) collected over
the disease course were tested for prolonged classical pathway activity, i.e. C4 nephritic factor (C4NeF) activity, and for prolonged alternative pathway activity, i.e. C3
nephritic factor (C3NeF) activity. Collection dates are presented as time after acute presentation in months (+mo). Hemolysis levels are presented as percentage of
full lysis of erythrocytes in water. Results are shown as mean and range of two independent experiments. Part Rem, partial remission; PC, positive control; NHS,
normal human serum; hi-NHS, heat-inactivated NHS.
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FIGURE 8 | Complement activation profiles of the patients with prolonged classical pathway convertase activity during follow-up. Follow-up is indicated as time after
initial presentation in months (mo). Grey areas indicate the healthy control ranges. DDD, dense deposit disease; C3GN, C3 glomerulonephritis; IC-MPGN, immune
complex-mediated membranoproliferative glomerulonephritis; CAU, complement arbitrary units.
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Electron microscopy showed subendothelial electron dense
deposits and presence of neutrophils. While on mycophenolate
mofetil and ACE inhibition, threemonths later his serum albumin
showed an increase (22 g/L) and his urinary protein/creatinine
ratio (610 mg/mmol) some decrease.
DISCUSSION
The C3G classification was introduced to replace the older term
MPGN in order to increase awareness of the AP dysregulation as
the central event in disease pathogenesis. Most frequently, AP-
directed autoantibodies are recognized as the underlying cause.
In most cases C3NeFs are identified, but in fewer cases
autoantibodies directed against Factor H, Factor B, or C3b can
be detected (2, 33). C3G is a very heterogenous disease and is
closely related to IC-MPGN. Although the autoimmune factors
causing AP dysregulation have been widely studied, less research
has focused on CP-specific dysregulating factors. Therefore, we
aimed to explore the involvement and characteristics of factors
dysregulating the CP convertase in C3G and IC-MPGN.
We validated a reliable and time-effective approach to screen
for CP convertase-stabilizing factors in the samples of 52 patients
whose samples were sent for C3G/IC-MPGN workup. We found
four patients whose sera showed prolonged CP convertase
activity: three patients with C3G and one patient with IC-
MPGN. In three patients (P1, P2, and P4), we could confirm
that Igs, i.e. autoantibodies named C4NeFs, were responsible for
prolonged CP convertase activity, since the Igs from these
patients induced convertase overactivation in NHS. This low
prevalence of C4NeF of 6% is in line with reported data in other
C3G/(IC-)MPGN patient cohorts, where the C4NeF prevalence
was 3-19% (16, 17, 19, 34). However, the Igs from one of our
patients (P3) did not support convertase stabilization when
added to NHS. This indicates that serum factors other than Igs
were present and responsible for the convertase overactivation in
this patient. Future research should aim at identifying the exact
nature of these types of serum factors. We hypothesize that this
patient may have a genetic variation in CP convertase proteins or
CP regulatory proteins, as has been described for a gain-of-
function mutation in C2 (35). Of note, we did not find any
aberrations in the C2 gene of patient P3.
Interestingly, all four patients showing prolonged CP
convertase activity also showed prolonged AP convertase
activity caused by C3NeFs. Such double positivity has been
shown previously in 20% (17), 41% (16), and 53% (19) of
C4NeF-postive C3G/MPGN patients, although isolated C4NeF
has also been reported in these studies. This overlap raises the
question of whether or not C3NeF and C4NeF activities can be
caused by the same antibody, at least in some cases. Using C3-
depleted serum, we observed that the Igs of our C4NeF-positive
patients (P1,P2, andP4) could stabilize theC4bC2aCPconvertases.
These convertases do not contain components (epitopes) that are
present in the C3bBb(P) convertases of the AP, which are stabilized
by C3NeFs. Furthermore, in previous studies we have convincingly
demonstrated that thisC4NeF detection assay specificallymeasures
CP and not AP activity. Convertase formation in this assay is
completely abolished by depletion of the CP components C1q and
C2 in test serum,while depletion of theAP component Factor B has
no significant effect (15, 35). Similarly, the C3NeF positivity of
patient Ig samples was determined in an AP-specific assay with a
buffer containing magnesium but lacking calcium. This eliminates
CP activity and only allows formation of AP convertases, which do
not contain C4NeF epitopes. Thus, these data strongly suggest that
the C3NeF and C4NeF activity in these patients is caused by
different clones of autoantibodies, rather than by an autoantibody
from a single B-cell clone.
Next to C3NeF and C4NeF activity, P2 and P4 also had rare
heterozygous genetic aberrations, whichmay indicate that multiple
factors have precipitated disease in these patients. Genetic analysis
revealed a missense variant in C3 [c.691A>C (p.Ser231Arg)] in
patientP2,whichhasnot beendescribedpreviously and ispredicted
as probably pathogenic by mutation prediction software (SIFT,
Align, and PolyPhen). In patient P4, a frameshift variant inCFHR5
[c.485_486dup (p.Glu163Lysfs*10)] was found, which leads to a
truncated protein. Similar frameshifts (p.Glu163Argfs*35) have
been previously described in C3G patients (36, 37) and in one
patient with atypical hemolytic uremic syndrome (38).
Overall, we observed that the patients with C4NeF activity
consistently showed strongly aberrant convertase activity and
complement biomarker profiles. First, in all four patients the
C3NeF and C4NeF activity remained present during the follow-
up, even though the patients all reached partial remission under
therapy. Of note, the C4NeF-positive patients we described did not
show an abnormal clinical presentation compared to C3G/IC-
MPGN patients without C4NeFs. Second, the complement
biomarker profiles during follow-up revealed strong, persistent
complement AP activation in all patients. C3 was highly
consumed and also the C5 levels were below control range,
whereas the activation markers C3bc, C3d, C3bBbP, and C5b-9
were all elevated. This indicates that complement was activated up
to the level of the terminal pathway and is consistent with previous
reports of C4NeF-positive C3G/IC-MPGN patients (16, 17, 34).
Previously, Zhang et al. showed that in their C3G cohort all the
C4NeF-positive patients showed low properdin levels (17). This was
also the case for the C4NeF-positive C3G patient found by Blom et
al. (34). In our study, three patients showed properdin levels that
were below the cut-off values. A highly activated complement
profile, as seen here in the C4NeF-positive patients, can also be
observed in certain C4NeF-negative (often C3NeF-positive) C3G/
IC-MPGN patients, but not in all and not always equally strong.
Prospective studies with longitudinal data collection are required to
further understand the role of C4NeF in C3G and IC-MPGN
pathogenesis and to investigate if C4NeF activity correlates with
clinical parameters and complement profiles.
Although AP activation persisted throughout follow-up in all
four patients, C4 levels were only decreased in two patients at
onset of the disease but normal in most of the other samples
analyzed. Normal C4 levels in patients with C4NeF have
frequently been reported before, and this is not surprising,
since both C3NeF and C4NeF stabilize C3 convertases and
eventually drive AP activation (16, 17, 34). Mechanisms known
to promote C4 consumption such as infection may play a role at
the beginning of the disease but are not continuously present in
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the patients, whereas intrinsic C3 activation drivers are (C3NeFs,
C4NeFs, and in some cases genetic changes).
Themain advantage of the assay for detection of CP convertase-
dysregulating factors described here is that the activity of the CP
convertases is examined in conditions inwhich all serum factors are
present to interact with the convertases. This allowed us to be the
first to identify factors prolonging CP convertase activity that were
not Igs inP3. Interestingly, we also found another patientwith non-
Ig-mediated CP convertase stabilization in the group of patients
with unknown diagnosis. This patient did not showC3NeF activity
and thus had isolated CP convertase dysregulation. Unfortunately,
no clinical data could be retrieved from this patient. Nonetheless, it
underlines that such factors would have been missed if only Ig
fractions from patients were tested. Furthermore, C4NeFs form a
heterogenous group, as do the C3NeFs: C4NeFs can prevent the
intrinsic and extrinsic decay of convertases to different extents by
interferingwithdifferent complement regulators (17, 24, 34, 39–41).
Therefore, studying the physiological environment of complete
serum enhances the likelihood of detecting relevant factors. Finally,
this serum approach allows a quick result and requires only a very
small amount of patient material.
In this study we have demonstrated that in C3G and IC-MPGN
CP convertase dysregulation may occur. Screening for these
abnormalities should be performed to carefully characterize the
complement defect in each patient which may affect the choice of
treatment.What still remains unknown is why and how individual
patients develop C4NeFs and to what extent they contribute to the
disease course, also when other factors such as C3NeFs are present.
C3G is a typical AP-mediated disease, but it is often preceded by an
infectious trigger. It is possible that the presence ofC4NeFs (or non-
Ig serum factors with C4NeF-like activity) exaggerate the initial
(weak) CP-mediated response, after which the disease evolves to a
primarily AP-driven disease process via the AP amplification loop,
especially if alsoC3NeFs are present. Similarly, it has beendescribed
that some patients with post-infectious glomerulonephritis may
evolve to C3G (42, 43).
In conclusion, we have shown in-depth analysis of CP convertase
activity in our C3G/IC-MPGN patient cohort and found that CP
convertaseoveractivation canbe causedbyC4NeFsbut alsoby serum
factors other than Igs that are still to be identified. Patients with
prolonged CP convertase activity additionally showed AP
dysregulation as seen by C3NeF activity and clear signs of full
complement activation in their blood. We recommend that all
patients with C3G and related diseases such as IC-MPGN are
tested for CP convertase-stabilizing factors for full characterization
of theunderlying complementdefect, especially in the light of a broad
spectrum of upcoming complement-inhibitors targeting the
complement pathways at different levels (44). Furthermore, future
research is needed to elucidate the exact role of CP convertase-
stabilizing factors in the initiation or progression of disease.
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